Indeterminate cell histiocytosis

Indeterminate cell histiocytosis is a rare type of histiocytosis, a group of diseases that involve an abnormal increase in the number of immune cells known as histiocytes. This condition is characterized by the presence of indeterminate cells, which are a type of histiocyte that has features of both Langerhans cells and non-Langerhans cells.

Symptoms

The symptoms of indeterminate cell histiocytosis can vary widely, but often include skin lesions that may be red or brown and can appear anywhere on the body. Other symptoms may include fever, fatigue, and weight loss. In some cases, the disease can affect internal organs such as the liver, spleen, and lymph nodes.

Causes

The exact cause of indeterminate cell histiocytosis is unknown. It is thought to be related to an abnormal response of the immune system, but the specific triggers are not well understood. It is not believed to be genetic or contagious.

Diagnosis

Diagnosis of indeterminate cell histiocytosis is often challenging due to its rarity and the nonspecific nature of its symptoms. It is typically confirmed through a biopsy of affected tissue, which is examined under a microscope to identify the presence of indeterminate cells.

Treatment

Treatment for indeterminate cell histiocytosis is typically aimed at managing symptoms and may include corticosteroids, chemotherapy, or radiation therapy. In some cases, surgery may be necessary to remove large or problematic lesions.

Prognosis

The prognosis for individuals with indeterminate cell histiocytosis can vary widely depending on the severity of the disease and the individual's overall health. Some people may experience a spontaneous remission, while others may have a chronic course with periods of worsening and improvement.

See also

• Histiocytosis
• Langerhans cell histiocytosis
• Non-Langerhans cell histiocytosis

Indeterminate cell histiocytosis Resources
Need Help Finding a Doctor? WikiMD's DocFinder can help find general and specialist physicians.	Latest articles Most recent articles Ongoing trials.